Procter & Gamble Health Limited has informed the Exchange regarding Board meeting held on November 05, 2025.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Procter & Gamble Health Limited approved the unaudited financial results for Q2 FY26 (quarter and six months ended September 30, 2025) at a meeting held on November 5, 2025. The statutory auditors, Haribhakti & Co. LLP, issued a clean limited review report with an unqualified opinion, noting nothing that would suggest material misstatement in the results. The document does not disclose any specific financial figures such as revenue, profit, or margins. Note 4 in the results explains that the six-month comparative figures for September 2024 were derived by aggregating separately published quarterly figures.
This is a routine quarterly results filing with no negative flags from the auditor. The clean limited review supports confidence in the reported numbers, though actual revenue and profit performance will need to be reviewed from the detailed results separately released by the company.